Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Citagenix Sale Announced this AM

<< Previous

Bullboard Posts

Next >>

Comment by Scotchnoiceon May 04, 2022 2:59am

156 Views

Post# 34653786

RE:RE:RE:RE:RE:Citagenix Sale Announced this AM

I had the chance to talk directly with Dan and the CGX team about their projects and business development plans for few hours and it didn't go according to plan at all!... In 2018 they were forecasting a revenue of 46m$ for FY24! Without any revenue from ATE technology...

I totaly understand why the acquisition of CGX was important for ATE towards investors but looking at CGX as a standalone company, they failed badly!

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale